BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Euronext Paris 16:09:52 22/05/2024 BST | ||
| 23.06 EUR | -0.68% |
|
| Current month | +4.11% | ||
| 1 month | +15.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 23.06 | -0.68% |
| 21/05/24 | 23.21 | +5.11% |
| 20/05/24 | 22.08 | +2.39% |
| 17/05/24 | 21.57 | -1.26% |
| 16/05/24 | 21.84 | -0.51% |
Real-time Euronext Paris
Last update May 22, 2024 at 04:09 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| ST86S | |
| ISIN | DE000SQ7URE8 |
| Date issued | 11/01/2023 |
| Strike | 304.5 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 3.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.65 € |
|---|---|
| Lowest since issue | 1.812 € |
| Spread | 0.057 € |
| Spread % | 0.25% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- ST86S Certificat
